Rhythm Biosciences Limited

CHIA:RHY Stock Report

Market Cap: AU$22.7m

Rhythm Biosciences Management

Management criteria checks 1/4

Rhythm Biosciences' CEO is David Atkins, appointed in May 2024, has a tenure of less than a year. total yearly compensation is A$409.24K, comprised of 12.1% salary and 87.9% bonuses, including company stock and options. directly owns 1.41% of the company’s shares, worth A$320.00K. The average tenure of the management team and the board of directors is 1.1 years and 1.1 years respectively.

Key information

David Atkins

Chief executive officer

AU$409.2k

Total compensation

CEO salary percentage12.1%
CEO tenureless than a year
CEO ownership1.4%
Management average tenure1.1yrs
Board average tenure1.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Atkins's remuneration changed compared to Rhythm Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$409kAU$49k

-AU$7m

Compensation vs Market: David's total compensation ($USD254.82K) is about average for companies of similar size in the Australian market ($USD290.31K).

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.


CEO

David Atkins (59 yo)

less than a year

Tenure

AU$409,243

Compensation

Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024 and serves as its Managing Director and Director since September 30, 2024. He was Director...


Leadership Team

NamePositionTenureCompensationOwnership
David Atkins
CEO, MD & Directorless than a yearAU$409.24k1.41%
A$ 320.0k
Guy Carisbrooke
Financial Controller1.3yrsAU$178.96kno data
Andrea Steele
General Counsel & Joint Company Secretary2.8yrsno datano data
James Barrie
Joint Company Secretaryless than a yearno datano data

1.1yrs

Average Tenure

Experienced Management: RHY's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
David Atkins
CEO, MD & Directorless than a yearAU$409.24k1.41%
A$ 320.0k
Otto Buttula
Non-Executive Chairman5.2yrsAU$369.11k12.83%
A$ 2.9m
Susan MacLeman
Independent Non-Executive Director1.9yrsAU$87.74kno data
Gavin Fox-Smith
Independent Non-Executive Directorno datano datano data

1.1yrs

Average Tenure

60yo

Average Age

Experienced Board: RHY's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 03:45
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rhythm Biosciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stuart RobertsPitt Street Research Pty Ltd.